EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu

Vasantha Mahalingam iD, Ramesh Kumar Santhanakrishnan, Muniyandi Malaisamy, Karthick Chelvanayagam, Kavi Mathiyazhagan, Adhin Bhaskar, Karikalan Nagarajan, Jerard Maria Selvam, Surendran Veeraiah, Kavitha Rajsekar, Kirti Tyagi, Ponnuraja Chinnaiyan

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0318013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Vasantha Mahalingam und 11 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-National Institute for Research in Tuberculosis, Chennai, India. Hauptthemen laut MEDLINE: Smoking Cessation, Cost-Benefit Analysis, Primary Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Smoking is a major public health concern in Tamil Nadu, as it is in many parts of the world. It is a leading cause of preventable diseases and deaths, with a significant economic burden on healthcare systems and society as a whole. Recognizing the need to address this issue, the implementation of smoking cessation strategies at primary health care (PHC) settings has gained attention. Conducting a cost-effectiveness analysis in this context can help policymakers and healthcare providers make informed decisions about the allocation of resources for such interventions.

Objectives

To compare the cost-effectiveness of the smoking cessation of proposed strategies (PSs), PS1: enhanced counselling (EC) + nicotine replacement therapy (NRT) + bupropion tablet; PS2: behavioural intervention (BI) + NRT + promotion of bupropion sustained release (SR); PS3: EC + NRT + promotion of bupropion SR with the current strategy (BI +NRT+ Bupropion) in a population of smokers aged ≥15 years attending the PHC in Tamil Nadu.

Methods

In this hypothetical cohort of 100,000 individuals using the decision tree analysis, a cost-effectiveness assessment was conducted for both proposed and existing strategies. The results were evaluated in terms of incremental cost-effectiveness ratios (ICERs) per person quitting smoking. To assess the robustness of the findings, one-way sensitivity analysis and probabilistic sensitivity analysis were performed which aims to explore and address the uncertainties associated with the outcomes.

Results

The cost of the current strategy (CS) was higher (₹359 or $4.28 million) when compared with PS1 (₹327 or $3.90 million) and PS3 (₹327 or $3.90 million) strategies. The PS2 with BI + bupropion SR + NRT was found to be more cost (₹2,720,571 or $ 32,414.76) as compared to current strategy. ICER values indicates that compared to the current strategy, the PS1 and PS3 were found to be cost-saving, whereas the PS2 was found to be cost-effective. The cost-effectiveness acceptability curve demonstrated that the PS1 and PS3 indicates 100% probability of the intervention being cost-saving. After excluding dominated interventions (PS2 and CS), the remaining strategies (PS1 and PS3) were compared. The PS3, with an incremental cost of ₹462,497 ($5,510) for 131 additional quitters, resulted in an ICER of ₹3,531 ($42) per quitter, making it a cost-effective option compared to PS1.

Conclusion

Our study findings indicate that the need for healthcare providers and policymakers to implement PS3 with EC, NRT, Bupropion SR, as which was found to be cost-saving compared to current practices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoking CessationCost-Benefit AnalysisPrimary Health CareHumansIndiaAdultBupropionFemaleMaleTobacco Use Cessation DevicesMiddle AgedAdolescentYoung AdultCounselingCost-Effectiveness Analysis

Substanzen

Bupropion

Autor:innen und Institutionen

  • ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • National Health Mission, Ministry of Health and Family Welfare, Government of Tamil Nadu, Chennai, India.
  • Department of Psycho-Oncology & RCTC, Cancer Institute (WIA), Chennai, India.
  • Department of Health Research, Ministry of Health and Family Welfare, New Delhi, India.

ORCID-Profile: Vasantha Mahalingam

Zitieren

APA

Mahalingam, V., Santhanakrishnan, R. K., Malaisamy, M., Chelvanayagam, K., Mathiyazhagan, K., Bhaskar, A., Nagarajan, K., Maria Selvam, J., Veeraiah, S., Rajsekar, K., Tyagi, K., & Chinnaiyan, P. (2025). Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu. PLOS ONE. https://doi.org/10.1371/journal.pone.0318013

Vancouver

Mahalingam V, Santhanakrishnan RK, Malaisamy M, Chelvanayagam K, Mathiyazhagan K, Bhaskar A, et al. Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu. PLOS ONE. 2025. doi:10.1371/journal.pone.0318013

BibTeX
@article{Mahalingam2025,
  author = {Mahalingam, Vasantha and Santhanakrishnan, Ramesh Kumar and Malaisamy, Muniyandi and Chelvanayagam, Karthick and Mathiyazhagan, Kavi and Bhaskar, Adhin and Nagarajan, Karikalan and Maria Selvam, Jerard and Veeraiah, Surendran and Rajsekar, Kavitha and Tyagi, Kirti and Chinnaiyan, Ponnuraja},
  title = {Cost-effectiveness analysis for implementation of smoking cessation strategies at primary health care settings in Tamil Nadu},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0318013}
}
Kostenlos starten →